> top > docs > PMC:7696151 > spans > 13057-15709 > annotations

PMC:7696151 / 13057-15709 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
402 593-596 Gene denotes CD4 Gene:920
403 1615-1618 Gene denotes CD4 Gene:920
404 1801-1804 Gene denotes CD4 Gene:920
405 2590-2597 Gene denotes HLA-B27 Gene:3106
406 1684-1687 Gene denotes CD8 Gene:925
407 342-350 Species denotes patients Tax:9606
408 404-412 Species denotes patients Tax:9606
409 823-831 Species denotes patients Tax:9606
410 950-958 Species denotes patients Tax:9606
411 1124-1132 Species denotes patients Tax:9606
412 1197-1205 Species denotes patients Tax:9606
413 1290-1298 Species denotes patients Tax:9606
414 2121-2129 Species denotes patients Tax:9606
415 2577-2584 Species denotes patient Tax:9606
416 49-52 Species denotes HIV Tax:12721
417 131-134 Species denotes HIV Tax:12721
418 2117-2120 Species denotes HIV Tax:12721
419 2447-2450 Species denotes HIV Tax:12721
420 54-57 Chemical denotes HCQ MESH:D006886
421 166-169 Chemical denotes HCQ MESH:D006886
422 212-223 Chemical denotes hydroxyurea MESH:D006918
423 243-253 Chemical denotes didanosine MESH:D016049
424 730-733 Chemical denotes HCQ MESH:D006886
425 735-746 Chemical denotes hydroxyurea MESH:D006918
426 752-762 Chemical denotes didanosine MESH:D016049
427 876-879 Chemical denotes HCQ MESH:D006886
428 888-899 Chemical denotes hydroxyurea MESH:D006918
429 916-926 Chemical denotes didanosine MESH:D016049
430 1465-1475 Chemical denotes didanosine MESH:D016049
431 1521-1524 Chemical denotes HCQ MESH:D006886
432 1738-1741 Chemical denotes HCQ MESH:D006886
433 2014-2017 Chemical denotes HCQ MESH:D006886
434 2019-2030 Chemical denotes hydroxyurea MESH:D006918
435 2036-2046 Chemical denotes didanosine MESH:D016049
436 2338-2341 Chemical denotes HCQ MESH:D006886
437 2463-2466 Chemical denotes HCQ MESH:D006886
438 327-341 Disease denotes HIV-1 infected MESH:D015658
439 804-816 Disease denotes HIV-infected MESH:D015658
440 1876-1888 Disease denotes HIV-infected MESH:D015658
441 2609-2646 Disease denotes spondyloarthropathy and HIV infection MESH:D015658

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T103 0-135 Sentence denotes Since monotherapy is not recommended in treating HIV, HCQ has also been tested in synergy with other drugs commonly used to manage HIV.
T104 136-385 Sentence denotes In this regard, 400 mg/day of HCQ in a combination regimen with 1000 mg/day hydroxyurea and 250–400 mg/day didanosine (dosed per body weight) was administered for 48 weeks to 22 asymptomatic HIV-1 infected patients naïve to antiretroviral treatment.
T105 386-428 Sentence denotes Only 16 out of 22 patients were evaluable.
T106 429-552 Sentence denotes These 16 subjects, at the 12th week, showed a significant reduction in viral load which was maintained until the 48th week.
T107 553-680 Sentence denotes Furthermore, at week 12, an increase in CD4+ percentage was also shown, and this improvement was kept until the 48th week [19].
T108 681-846 Sentence denotes To evaluate the long-term efficacy and safety of HCQ, hydroxyurea, and didanosine combination, they were also tested on 17 HIV-infected naïve patients for 144 weeks.
T109 847-939 Sentence denotes All subjects received 200 mg HCQ, 500 mg hydroxyurea, and 125–200 mg didanosine twice daily.
T110 940-1026 Sentence denotes Of the 17 patients who started treatment, 14 remained until the end of the 144th week.
T111 1027-1284 Sentence denotes After 114 weeks, viral load was reduced by 1.6 Log10 copies/mL under baseline (p < 0.001), eight patients (47%) had an unnoticeable viral load (< 400 copies/mL), and two patients (12%) had a measurable viral load, but resistance mutations were not detected.
T112 1285-1525 Sentence denotes Four patients (24%) had both detectable viral load and resistance mutation: one with both 62V and 65R and three with both 74V and 184V mutations; the latter three were assessed as didanosine resistant, while no resistance was found for HCQ.
T113 1526-1610 Sentence denotes However, in all cases, the viral load remained below the baseline at the 144th week.
T114 1611-1732 Sentence denotes The CD4+ cell count had increased significantly, while the percentage of CD8 cells was reduced up to the 144th week [20].
T115 1733-1965 Sentence denotes This HCQ noticeable impact on immune activation, thereby increasing CD4+ T cells, was also demonstrated in a prospective study conducted on 20 HIV-infected immunologic no responders treated with standard antiretroviral therapy [23].
T116 1966-2130 Sentence denotes These results suggested that the combination of HCQ, hydroxyurea, and didanosine could be a valid alternative to the highly active commercial HAART in HIV-patients.
T117 2131-2269 Sentence denotes Nonetheless, these latter studies have some limitations, such as the small number of subjects included and the absence of a control group.
T118 2270-2419 Sentence denotes Therefore, it is not possible to determine the contribution made by HCQ to the overall decrease in viral load obtained from the combination of drugs.
T119 2420-2652 Sentence denotes Anyway, the potential anti-HIV efficacy of HCQ, when added to existing treatment with an antiretroviral regimen, was also confirmed by a case report about a patient with HLA-B27-associated spondyloarthropathy and HIV infection [43].